Information regarding the specific cost of Xofluza is not readily available in the provided context. Drug pricing can vary significantly based on factors such as insurance coverage, geographic location, and pharmacy.
How is Xofluza prescribed?
Xofluza is typically prescribed as a single oral dose [1]. It is used for the treatment of acute uncomplicated influenza in individuals aged 12 years and older who have been symptomatic for no more than 48 hours [1]. It is also used for the preventive treatment of influenza in individuals aged 12 years and older after exposure [1].
What are the approved uses for Xofluza?
Xofluza, with the active ingredient baloxavir marboxil, is approved for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been experiencing symptoms for 48 hours or less [1]. It is also indicated for the preventive treatment of influenza in individuals 12 years of age and older following close contact with someone who has influenza [1].
Who manufactures Xofluza?
Xofluza is manufactured by Shionogi Inc. [1].
What is the mechanism of action for Xofluza?
Xofluza is a first-in-class cap-dependent endonuclease inhibitor. It works by inhibiting the activity of the viral endonuclease enzyme, which is essential for viral gene transcription [1]. By blocking this enzyme, Xofluza prevents the virus from replicating.
What are the potential side effects of Xofluza?
Common side effects reported in clinical trials include diarrhea, bronchitis, nausea, and sinus congestion [1]. In some cases, more serious side effects may occur.
When does Xofluza's patent protection expire?
Information regarding the specific patent expiry dates for Xofluza is not available in the provided text. Drug patent information can be complex and may involve multiple patents covering different aspects of the drug's composition, manufacturing, and use. Resources like DrugPatentWatch.com track these details.